Moss-aGal (recombinant human alpha-galactosidase A produced in moss)

( DrugBank: - / KEGG DRUG: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
19	ライソゾーム病	1

19. ライソゾーム病

臨床試験数 : 899 / 薬物数 : 684 - (DrugBank : 99) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 182

trials per page:

Showing 1 to 1 of 1 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02995993 (ClinicalTrials.gov)	November 2016	14/12/2016	Pharmacokinetics, Pharmacodynamics, and Safety of Moss-aGalactosidase A inPatients With Fabry Diseas ...	An Open-Label, Multi-Center Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of ...	Fabry Disease	Drug: Moss-aGal (recombinant human alpha-galactosidase A produced in moss)	Greenovation Biotech GmbH	FGK Clinical Research GmbH	Completed	18 Years	65 Years	All	6	Phase 1	Germany

First Previous1Next Last